Abstract
Carcinoma prostate is among the most common cancers worldwide and is mainly treated in metastatic settings through androgen blockade or chemotherapy. Homologous repair deficiency is fairly common (germline and somatic) and allows targeted therapy through poly ADP-ribose polymerases (PARP) inhibitors. While data backing monotherapy is strong, recent evidence seems to support frontline combination therapy as well. Genetic testing of prostate cancer patients also needs personalization. Pre-clinical and early clinical data have provided insights into mechanisms and management of therapy resistance as well. This narrative review deals with the optimal patient selection and the evidence behind PARP inhibitor therapy in cases of metastatic carcinoma prostate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Molecular and Immuno Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
